Previous 10 | Next 10 |
Agenus Inc. (NASDAQ:AGEN) traded at a new 52-week high today of $6.36. So far today approximately 8.4 million shares have been exchanged, as compared to an average 30-day volume of 2.8 million shares. Agenus Inc. (NASDAQ:AGEN) defies analysts with a current price ($6.27) 7.9% above its a...
Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumors Responses seen across all histology subgroups including populations of patients unresponsive to other therapies LEXINGTON, Mass., Aug. 26, 2021 (G...
In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-care. The broader clinical/investment community may see much faster patient enrollment t...
Agenus Inc. (NASDAQ:AGEN) traded today at a new 52-week high of $6.30. Approximately 8.4 million shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares. Agenus Inc. share prices have moved between a 52-week high of $6.30 and a 52-week low of $2.50 ...
Agenus made a potentially $1.5 billion deal with Bristol Myers in May. Balstilimab PDUFA date is December 16, 2021. Multiple other value-adding events are possible in 2021-2022. For further details see: Agenus Multiple Value-Adding Events Ahead
Agenus Inc. (NASDAQ:AGEN) traded at a new 52-week high today of $6.16. Approximately 8.4 million shares have changed hands today, as compared to an average 30-day volume of 2.5 million shares. Agenus Inc. (NASDAQ:AGEN) is currently priced 7.7% above its average consensus analyst price ta...
Agenus Inc. (NASDAQ:AGEN) traded today at a new 52-week high of $5.96. Approximately 8.4 million shares have changed hands today, as compared to an average 30-day volume of 2.5 million shares. Potential upside of 2.7% exists for Agenus Inc., based on a current level of $5.93 and analysts...
Biotech Stocks Are Red Hot In 2021 Finding hot industries is always a favored research topic whether you’re trading penny stocks or higher-priced names. Right now, a few of the hottest to watch this year are biotechnology and healthcare. While you might think that coronav...
Agenus (NASDAQ: AGEN) , a darling stock earlier this year, wasn't looking too attractive on Monday. The cancer-focused biotech's shares sank by 4.1% on the day following its second-quarter earnings release. For the quarter, Agenus saw its revenue shrink to $10.7 million from the...
Image source: The Motley Fool. Agenus inc (NASDAQ: AGEN) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus inc (AGEN) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...